Black Rock Inc. Bellerophon Therapeutics, Inc. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.38 - $0.76 $818 - $1,636	-2,153 Reduced 1.66%	127,723 $51,000
Q2 2023 Aug 11, 2023	BUY	$0.68 - $12.39 $22,798 - $415,399	33,527 Added 34.8%	129,876 $89,000
Q1 2023 May 12, 2023	SELL	$0.9 - $7.89 $3,848 - $33,737	-4,276 Reduced 4.25%	96,349 $760,000
Q2 2022 Aug 12, 2022	SELL	$0.85 - $2.36 $17,054 - $47,351	-20,064 Reduced 16.62%	100,625 $124,000
Q1 2022 May 12, 2022	SELL	$1.82 - $3.24 $1,785 - $3,178	-981 Reduced 0.81%	120,689 $285,000
Q4 2021 Feb 10, 2022	BUY	$2.36 - $4.05 $2,478 - $4,252	1,050 Added 0.87%	121,670 $378,000
Q3 2021 Nov 09, 2021	BUY	$3.75 - $4.86 $15,517 - $20,110	4,138 Added 3.55%	120,620 $490,000
Q2 2021 Aug 11, 2021	BUY	$3.83 - $5.65 $446,126 - $658,123	116,482 New	116,482 $564,000

44K

Ticker BLPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,545,450
Market Cap $382K
Description
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.